A new publication related to MC4R agonist research was released on August 10, 2026. The paper, titled "Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity," appeared in the Journal of Medicinal Chemistry.
The publication describes TL10, a compound identified as an MC4R agonist with tunable lipidation designed for sustained pharmacological activity, according to the title. Setmelanotide, an approved MC4R agonist, is referenced here as context for the broader class of MC4R-targeting compounds under study.
No findings, efficacy data, or safety outcomes from the publication were provided beyond the title and journal listing. This brief reports only that the publication exists and where it was published, without characterizing its results or conclusions.
Readers interested in the pharmacology of MC4R agonists, including approved therapies like setmelanotide, can consult the compound overview for additional background and regulatory context.